- Home
- LCTX vs FSHP Comparison
LCTX vs FSHP Comparison
Compare LCTX & FSHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FSHP
- Stock Information
- Founded
- LCTX 1990
- FSHP 2018
- Country
- LCTX United States
- FSHP United States
- Employees
- LCTX N/A
- FSHP N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FSHP
- Sector
- LCTX Health Care
- FSHP
- Exchange
- LCTX Nasdaq
- FSHP NYSE
- Market Cap
- LCTX 107.3M
- FSHP 92.2M
- IPO Year
- LCTX N/A
- FSHP 2024
- Fundamental
- Price
- LCTX $0.70
- FSHP $10.42
- Analyst Decision
- LCTX Strong Buy
- FSHP
- Analyst Count
- LCTX 5
- FSHP 0
- Target Price
- LCTX $4.20
- FSHP N/A
- AVG Volume (30 Days)
- LCTX 1.5M
- FSHP 3.2K
- Earning Date
- LCTX 08-07-2025
- FSHP 01-01-0001
- Dividend Yield
- LCTX N/A
- FSHP N/A
- EPS Growth
- LCTX N/A
- FSHP N/A
- EPS
- LCTX N/A
- FSHP 0.21
- Revenue
- LCTX $9,557,000.00
- FSHP N/A
- Revenue This Year
- LCTX N/A
- FSHP N/A
- Revenue Next Year
- LCTX $232.66
- FSHP N/A
- P/E Ratio
- LCTX N/A
- FSHP $48.99
- Revenue Growth
- LCTX 19.42
- FSHP N/A
- 52 Week Low
- LCTX $0.37
- FSHP $9.99
- 52 Week High
- LCTX $1.15
- FSHP $10.48
- Technical
- Relative Strength Index (RSI)
- LCTX 62.72
- FSHP N/A
- Support Level
- LCTX $0.48
- FSHP N/A
- Resistance Level
- LCTX $0.83
- FSHP N/A
- Average True Range (ATR)
- LCTX 0.06
- FSHP 0.00
- MACD
- LCTX 0.01
- FSHP 0.00
- Stochastic Oscillator
- LCTX 60.76
- FSHP 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.